By: Krista Hutchins
June 8, 2017
The Wright Center is helping Dr. Fowler continue his research and make national news!
Collaboration and Community Core leader, Dr. Alpha “Berry” Fowler, is in the news for his work with Vitamin C and Sepsis. He is making headlines locally and nationally for his continued research and success with the treatment of sepsis using high doses of Vitamin C.
“Did you know that bacterial, viral, and fungal sepsis kills more than 350,000 Americans each year?” Dr. Fowler says to think of two fully loaded 747’s crashing every day. “That will you give you an understanding of the number of lives lost each year.”
The Wright Center, he says, has helped him move forward with the performance of a double blind, placebo-controlled trial, examining the extent to which a simple intervention with intravenous vitamin C can save lives for sepsis.
He credits the Wright Center for providing the necessary resources for everything from interdisciplinary human health research at VCU, to grant writing and biostatistics support to data resources and clinical research services support.
“I was able to use several Wright Center Research Innovators.” Adding, “I used the amazing grant writing services of Bonnie Quearry-together we addressed the problem of sepsis and began the process of writing.” Fowler says, in the end, the grant was broad-based and expertly written. He goes on to say, Dr. Pamela Dillon, Research Liason, helped write the budget for the grant, and Dr. Leroy Thacker, biostatistician, helped with the statistics needed from our Phase 1 drug trial and knowing the proper outcomes to use.
Finally, he says, “I have made great use of the Wright Center’s RedCap Database capture system to log all the clinical data obtained from patients enrolled at each study site.” The study sites are as follows: Virginia Commonwealth University (lead), The Cleveland Clinic, The Medical College of Wisconsin, and the University of Kentucky.
After a 3 year, 3.2 million dollar grant from NIH, obtained with the help of Wright Center professionals, 140 patients have been enrolled in the trial, which is still ongoing.